BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 11789735)

  • 1. A formalin-fixed, paraffin-processed cell line standard for quality control of immunohistochemical assay of HER-2/neu expression in breast cancer.
    Rhodes A; Jasani B; Couturier J; McKinley MJ; Morgan JM; Dodson AR; Navabi H; Miller KD; Balaton AJ
    Am J Clin Pathol; 2002 Jan; 117(1):81-9. PubMed ID: 11789735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of HER-2/neu immunohistochemical assay sensitivity and scoring on formalin-fixed and paraffin-processed cell lines and breast tumors: a comparative study involving results from laboratories in 21 countries.
    Rhodes A; Jasani B; Anderson E; Dodson AR; Balaton AJ
    Am J Clin Pathol; 2002 Sep; 118(3):408-17. PubMed ID: 12219783
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization.
    Pauletti G; Godolphin W; Press MF; Slamon DJ
    Oncogene; 1996 Jul; 13(1):63-72. PubMed ID: 8700555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of HER-2/neu status in breast cancer. Automated Cellular Imaging System (ACIS)-assisted quantitation of immunohistochemical assay achieves high accuracy in comparison with fluorescence in situ hybridization assay as the standard.
    Wang S; Saboorian MH; Frenkel EP; Haley BB; Siddiqui MT; Gokaslan S; Wians FH; Hynan L; Ashfaq R
    Am J Clin Pathol; 2001 Oct; 116(4):495-503. PubMed ID: 11601134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitation of HER-2/neu oncoprotein overexpression in invasive breast cancer by image analysis: a study comparing fresh and paraffin-embedded material.
    van Diest PJ; Baak JP; Chin D; Theeuwes JW; Bacus SS
    Anal Cell Pathol; 1991 Jul; 3(4):195-202. PubMed ID: 1679345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HER-2/neu detection in fine-needle aspirates of breast cancer: fluorescence in situ hybridization and immunocytochemical analysis.
    Beatty BG; Bryant R; Wang W; Ashikaga T; Gibson PC; Leiman G; Weaver DL
    Am J Clin Pathol; 2004 Aug; 122(2):246-55. PubMed ID: 15323142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HER-2/neu evaluation by immunohistochemistry and fluorescence in situ hybridization in breast cancer: implications for daily laboratory practice.
    Larsimont D; Di Leo A; Rouas G; Paesmans M; Ferreira-Filho F; Bernard C; Cardoso F; Verhest A; Piccart MJ; Gancberg D
    Anticancer Res; 2002; 22(4):2485-90. PubMed ID: 12174949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of HER-2/neu expression in prostatic adenocarcinoma: a requested for a standardized, organ specific methodology.
    Sanchez KM; Sweeney CJ; Mass R; Koch MO; Eckert GJ; Geary WA; Baldridge LA; Zhang S; Eble JN; Cheng L
    Cancer; 2002 Oct; 95(8):1650-5. PubMed ID: 12365012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of immunohistochemistry by automated cellular imaging system (ACIS) versus fluorescence in-situ hybridization in the evaluation of HER-2/neu expression in primary breast carcinoma.
    Tawfik OW; Kimler BF; Davis M; Donahue JK; Persons DL; Fan F; Hagemeister S; Thomas P; Connor C; Jewell W; Fabian CJ
    Histopathology; 2006 Feb; 48(3):258-67. PubMed ID: 16430472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Detection of HER-2/neu in breast carcinoma].
    Skálová A; Vanĕcek T; Losan F; Papoutsidesová ; Fínek J
    Cas Lek Cesk; 2003 Feb; 142(2):93-8. PubMed ID: 12698536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aneusomy 17 in breast cancer: its role in HER-2/neu protein expression and implication for clinical assessment of HER-2/neu status.
    Wang S; Hossein Saboorian M; Frenkel EP; Haley BB; Siddiqui MT; Gokaslan S; Hynan L; Ashfaq R
    Mod Pathol; 2002 Feb; 15(2):137-45. PubMed ID: 11850542
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Her-2/neu expression and amplification in early stage ovarian surface epithelial neoplasms.
    Wu Y; Soslow RA; Marshall DS; Leitao M; Chen B
    Gynecol Oncol; 2004 Dec; 95(3):570-5. PubMed ID: 15581965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemical determination of HER-2/neu expression in invasive breast carcinoma.
    Vang R; Cooley LD; Harrison WR; Reese T; Abrams J
    Am J Clin Pathol; 2000 May; 113(5):669-74. PubMed ID: 10800399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry.
    Pauletti G; Dandekar S; Rong H; Ramos L; Peng H; Seshadri R; Slamon DJ
    J Clin Oncol; 2000 Nov; 18(21):3651-64. PubMed ID: 11054438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HER-2/neu analysis in breast cancer bone metastases.
    Zustin J; Boddin K; Tsourlakis MC; Burandt E; Mirlacher M; Jaenicke F; Izbicki J; Ruether W; Rueger JM; Bokemeyer C; Simon R; Sauter G
    J Clin Pathol; 2009 Jun; 62(6):542-6. PubMed ID: 19474354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HER-2 testing in breast cancer using immunohistochemical analysis and fluorescence in situ hybridization: a single-institution experience of 2,279 cases and comparison of dual-color and single-color scoring.
    Lal P; Salazar PA; Hudis CA; Ladanyi M; Chen B
    Am J Clin Pathol; 2004 May; 121(5):631-6. PubMed ID: 15151202
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of the HER-2/neu oncogene by immunohistochemical and fluorescence in situ hybridization analysis in oral and oropharyngeal squamous cell carcinoma.
    Khan AJ; King BL; Smith BD; Smith GL; DiGiovanna MP; Carter D; Haffty BG
    Clin Cancer Res; 2002 Feb; 8(2):540-8. PubMed ID: 11839675
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-time reverse transcription-PCR and fluorescence in-situ hybridization are complementary to understand the mechanisms involved in HER-2/neu overexpression in human breast carcinomas.
    Vanden Bempt I; Vanhentenrijk V; Drijkoningen M; Wlodarska I; Vandenberghe P; De Wolf-Peeters C
    Histopathology; 2005 Apr; 46(4):431-41. PubMed ID: 15810955
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Flow cytometry: a new approach for the molecular profiling of breast cancer.
    Lostumbo A; Mehta D; Setty S; Nunez R
    Exp Mol Pathol; 2006 Feb; 80(1):46-53. PubMed ID: 16271361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Her-2/neu in barrett esophagus: a comparative study between histology, immunohistochemistry, and fluorescence in situ hybridization.
    Rossi E; Villanacci V; Bassotti G; Casa DD; Missale G; Minelli L; Cestari R
    Diagn Mol Pathol; 2006 Sep; 15(3):125-30. PubMed ID: 16932066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.